Browse by author
Lookup NU author(s): Dr David Sheridan, Dr David Price, Dr Matthias Schmid, Emeritus Professor Geoffrey Toms, Dr Peter Donaldson, Dr R Neely, Professor Margaret Bassendine
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Hepatitis C virus (HCV) co-opts very-low-density lipoprotein (VLDL) pathways for replication, secretion and entry into hepatocytes and associates with apolipoprotein B (apoB) in plasma. Each VLDL contains apoB-100 and variable amounts of apolipoproteins E and C, cholesterol and triglycerides. To determine whether baseline lipid levels predicted treatment outcome. Retrospective analysis was performed of 250 chronic hepatitis C (CHC) patients who had received anti-viral agents interferon-alpha and ribavirin; 165 had a sustained virological response (SVR). Pre- and post-treatment nonfasting lipid profiles were measured and non-high-density lipoprotein (non-HDL) cholesterol (i.e. apoB-associated) was calculated. Binary logistic regression analysis assessed factors independently associated with treatment outcome. There was an independent association between higher apoB-associated cholesterol (non-HDL-C) and increased odds of SVR (odds ratio 2.09, P = 0.042). In multivariate analysis, non-HDL-C was significantly lower in HCV genotype 3 (g3) than genotype 1 (P = 0.007); this was reversible upon eradication of HCVg3 (pre-treatment non-HDL-C = 2.8 mmol/L, SVR = 3.6 mmol/L, P
Author(s): Sheridan DA, Price DA, Schmid ML, Toms GL, Donaldson P, Neely D, Bassendine MF
Publication type: Article
Publication status: Published
Journal: Alimentary Pharmacology & Therapeutics
Year: 2009
Volume: 29
Issue: 12
Pages: 1282-1290
Date deposited: 18/05/2010
ISSN (print): 0269-2813
ISSN (electronic): 1365-2036
Publisher: Wiley-Blackwell Publishing Ltd.
URL: http://dx.doi.org/10.1111/j.1365-2036.2009.04012.x
DOI: 10.1111/j.1365-2036.2009.04012.x
Altmetrics provided by Altmetric
